In the October 1999 (vol. 9, no. 4) issue of this newsletter (Also in CMAJ 1999;161[7]:867) an article was published on serious hematologic reactions associated with ticlopidine. The recommendations provided in the last paragraph regarding the monitoring of the leukocyte count should have read as follows (corrected text in italics):
Hematologic monitoring of the leukocyte count along with a differential and a platelet count is recommended at baseline and every 2 weeks to the end of the third month of therapy with ticlopidine. If therapy has been discontinued within the first 90 days, an additional complete blood count with differential should be done 2 weeks after the discontinuation of therapy because of the long half-life of ticlopidine (terminal elimination half-life 4-5 days).
These recommendations are consistent with the product monograph. We apologize for any confusion this may have caused.